How should the usage and dosage of colexitinib/sondido be adjusted?

Deucravacitinib is very easy to administer, and one of its advantages is that it is a fixed-dose oral regimen. According to recommendations from mainstream overseas instructions, the common dosage is 6 mg once daily, and no routine adjustments are required due to weight, gender or mild renal impairment. This simplified dosing model greatly improves compliance and is especially convenient for patients with plaque psoriasis who require long-term treatment.

However, in clinical practice, individualized adjustment is still a link that cannot be ignored. First, in patients with moderate to severe hepatic impairment, medication use should be carefully evaluated because the drug is metabolized in the liver and abnormal liver function may affect its plasma concentration. Secondly, for patients who are combined with multiple immunosuppressants or potent CYP enzyme inhibitors, doctors usually monitor blood drug concentrations or adjust dosing plans to reduce the risk of drug interactions.

Another group of people who need special attention are patients with chronic infections or underlying immune system diseases. Although the selective targeting properties of deuterated colexitinib reduce the risk of some adverse effects, it may still increase the chance of infection in immunosuppressed states. Therefore, it is clinically recommended to screen patients for latent infections such as tuberculosis and hepatitis B before treatment to ensure the safety of medication.

In addition, during long-term treatment, if the patient experiences persistent leukopenia, elevated liver enzymes, or repeated clinical symptoms, he or she should communicate with the doctor in a timely manner and suspend or adjust treatment if necessary. It is worth noting that deuterated coxitinib does not take effect immediately, and its improvement in skin lesions usually takes weeks or even months of continuous medication to appear. Therefore, patients should not increase or decrease the dose or interrupt the treatment course on their own to avoid affecting the efficacy.

In summary, the standard dosage setting of deuterated colexitinib is relatively fixed, which greatly simplifies the operational complexity of long-term treatment of psoriasis. However, in the case of special groups or combined medications, personalized adjustments still need to be made based on individual differences and laboratory monitoring results to ensure a balance between efficacy and safety.

Reference materials:https://go.drugbank.com/drugs/DB16650